Try Alerts Free   |   Login
Health Care › Services-Medical Laboratories

PSNL Price Correlated With Financials For Personalis

Free historical financial statements for Personalis Inc. See how revenue, income, cash flow, and balance sheet financials have changed over 12 quarters since 2019. Compare with PSNL stock chart to see long term trends.

PSNL Stock Compared to Quarterly

PSNL Income Statement

Revenue, Net:15227000
Revenue Per Share:0.3351
Cost of Goods & Services Sold:10949000
Selling, General & Admin Expense:15486000
Research & Development Expense:17098000
Total Operating Expenses:43533000
Operating Income:-28306000
Income Taxes:7000
Net Income:-28209000
Earnings Per Share, Basic:-0.63
Shares Outstanding, Basic Avg:45446930

PSNL Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:1774000
Change in Accounts Receiveable:-4949000
Net Cash from Operations:-11357000
Net Cash from Operations Per Share:-0.2499
Cash Dividends Paid:0
Net Cash from Financing Activities:515000
Property, Plant & Equipment Purchases:8634000
Net Cash from Investing Activities:-3161000
Net Change in Cash & Equivalents:-13999000

PSNL Balance Sheet

Cash and Cash Equivalents:93376000
Short-Term Investments:174954000
Accounts Receivable, Net:13519000
Total Current Assets:294028000
Property, Plant & Equipment, Net:30600000
Total Assets:380647000
Accounts Payable:12275000
Total Short-Term Liabilities:39844000
Total Liabilities:93932000

Insider Trading

 
Change
Value
Transaction
SEC Form 4
Lightspeed Venture Partners Select IV, L.P.   Affiliate of 10% Owner
4,750 sh at $10
$49,305
Buy
COMPANY PROFILE
Note 1. Company and Nature of Business
Personalis, Inc. (the “Company”) was incorporated in Delaware on February 21, 2011 and began operations in September 2011. The Company formed a wholly owned subsidiary, Personalis (UK) Ltd., in August 2013 and a wholly owned subsidiary, Shanghai Personalis Biotechnology Co., Ltd., which is referred to as “Personalis (Shanghai) Ltd” herein, in October 2020. The Company is a provider of advanced genetic tests for cancer. The Company also provides sequencing and data analysis services to support population sequencing initiatives, which accounts for the majority of its revenue. The Company’s genetic tests for cancer are sold primarily to pharmaceutical companies, biopharmaceutical companies, universities, non-profits, and government entities, while services for population sequencing initiatives are sold primarily to government entities. The principal markets for the Company’s services are in the United States and Europe. In June 2020, the Company began partnering with a clinical genomics and life sciences company headquartered in China to expand business operations into China. The Company operates and manages its business as one reportable operating segment, which is the sale of sequencing and data analysis services.
The Company has incurred losses to date and expects to incur additional losses for the foreseeable future. The Company continues to invest the majority of its resources in the development and growth of its business, including investments in product development and sales and marketing efforts. The Company’s activities have been financed to date primarily through the sale of its equity securities and cash from operations.

Data imported from Personalis Inc SEC filings. Check original filings before making any investment decision.